Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Castle Biosciences, Inc. - Common stock (NQ:CSTL)

22.14 -0.39 (-1.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Castle Biosciences, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
From Castle Biosciences, Inc.
Via GlobeNewswire
Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences Celebrates Skin Cancer Awareness Month
From Castle Biosciences, Inc.
Via GlobeNewswire
Earnings Scheduled For May 5, 2025
 
Via Benzinga
Earnings Scheduled For February 27, 2025
 
Via Benzinga
Beyond The Numbers: 7 Analysts Discuss Castle Biosciences Stock
 
Via Benzinga
Nike To $70? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
Castle Biosciences Reports First Quarter 2025 Results
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences to Acquire Previse
From Castle Biosciences, Inc.
Via GlobeNewswire
New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer
From Castle Biosciences, Inc.
Via GlobeNewswire
New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity
From Castle Biosciences, Inc.
Via GlobeNewswire
DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma
From Castle Biosciences, Inc.
Via GlobeNewswire
New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year
From Castle Biosciences, Inc.
Via GlobeNewswire
Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups
From Castle Biosciences, Inc.
Via GlobeNewswire
New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Participate in Upcoming Investor Conferences
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii®
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025
From Castle Biosciences Inc.
Via Business Wire
Castle’s Poster on DecisionDx®-SCC Selected as a “Late Breakers” Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett’s Esophagus Test
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Castle Biosciences Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.